These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 7750902

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K, Althoff PH, Harris A, Hofmeister-Wagner W, Schifferdecker E, Schöffling K.
    Med Klin (Munich); 1990 Dec 15; 85(12):700-6. PubMed ID: 2128367
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Reevaluation of the I-dopa test in acromegaly: anatomo-clinical and prognostic correlations].
    De Marinis L, Mancini A, Zuppi P, Fiumara C, Iacona T, Conte G, Fabrizi ML, Valle D, Anile C, Maira G.
    Minerva Chir; 1993 Nov 15; 48(21-22):1337-40. PubMed ID: 8152567
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF, van Liessum PA, Smals AG, van Gennep JA, Benraad TJ, Kloppenborg PW.
    Acta Endocrinol Suppl (Copenh); 1987 Nov 15; 286():9-18. PubMed ID: 2892339
    [Abstract] [Full Text] [Related]

  • 14. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
    De Marinis L, Mancini A, Bianchi A, Gentilella R, Valle D, Giampietro A, Zuppi P, Anile C, Maira G, Giustina A.
    Metabolism; 2002 May 15; 51(5):616-21. PubMed ID: 11979395
    [Abstract] [Full Text] [Related]

  • 15. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR, Toogood AA, Veldhuis JD, Thorner MO, Shalet SM.
    J Clin Endocrinol Metab; 2001 Jan 15; 86(1):259-66. PubMed ID: 11232010
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide.
    Díez JJ, Iglesias P, Gómez-Pan A.
    J Endocrinol Invest; 2001 May 15; 24(5):303-9. PubMed ID: 11407648
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly.
    Hattori N, Shimatsu A, Kato Y, Koshiyama H, Ishikawa Y, Assadian H, Tanoh T, Nagao M, Imura H.
    J Clin Endocrinol Metab; 1990 Mar 15; 70(3):771-6. PubMed ID: 2106529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.